

Predicted epitopes of HA, NA, and M2 protein using IEDB T-cell epitope prediction tool

A. Soltabayeva¹, A. Chinybayeva¹, S. Zhussupbekova¹, A. Kabdullina¹ and K. Alibek²

¹Nazarbayev University Research and Innovation System, Nazarbayev University, Kazakhstan

²School of science and technology, Nazarbayev University, Kazakhstan

Vaccination against circulating strains of seasonal influenza viruses is known as the primary weapon to battle influenza epidemics. Identification of protective immunogens allows using synthetic peptides as a vaccine. Hemagglutinin, neuraminidase, and M2 protein T-cell epitopes of three influenza virus strains H1N1 (n = 1136), H3N2 (n = 1233), and H5N1 (n = 79) were predicted by using IEDB T-cell Epitope Prediction Tool. Predicted epitopes bind to both MHC class I and class II alleles. Epitopes predicted with IC₅₀ value lower 50 were selected. Hemagglutinin conserved epitopes in position 360–368 binds to MHC class I alleles HLA-A*29:02, HLA-A*30:02, and HLA-B*15:02; epitope sequence in position 436–444 binds to MHC class I allele HLA-A*02:06. M2 protein T-cell epitope in position 3–11 binds to MHC class I alleles HLA-A*02:01 and HLA-A*02:06, epitope in position 45–53 of M2 protein binds to MHC class I alleles HLA-A*31:01, HLA-A*03:01, and HLA-A*11:01. Neuraminidase epitope in position 38–46 binds to MHC class II alleles HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DQA1*01:01/DQB1*05:01, HLA-DRB1*04:04, and HLA-DRB4*01:01, epitope of neuraminidase in position 47–55 binds to MHC class II alleles HLA-DPB1*03:01/DPB1*04:01, HLA-DPA1*01/DPB1*04:01, HLA-DPA1*01:03/DPB1*02:01, HLA-DPA1*02:01/DPB1*01:01, HLA-DPA1*03:01/DPB1*04:02, HLA-DPB1*03:01/DPB1*04:01, HLA-DRB1*07:01, HLA-DRB1*11:01, HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-DRB5*01:01, and HLA-DRB1*11:01. Our predicted epitopes by using IEDB T-cell Epitope Prediction Tool confirm referenced epitopes. The epitopes are conserved and have affinity to several MHC class I and II alleles, therefore they can be considered as potential candidates for influenza vaccine. Our further study will be *in vivo* analysis of predicted epitopes in different combinations for finding the most immunogenic combination.

aigerim.soltabayeva@nu.edu.kz